Clinical Trials · NCT03822468
Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Novartis Pharmaceuticals
- Enrollment
- 376
- Start date
- Jun 2019
- Locations
- 89 sites, 23 countries
- Primary endpoint
- Overall Response Rate (ORR)